The Propeptide Binding Site of the Bovine gamma -Glutamyl Carboxylase*

(Received for publication, February 6, 1997)

Sheue-Mei Wu Dagger , Vasantha P. Mutucumarana Dagger , Scott Geromanos § and Darrel W. Stafford Dagger

From the Dagger  Biology Department, University of North Carolina, Chapel Hill, North Carolina 27599-3280 and § Sloan-Kettering Institute for Cancer Research, Rockefeller Research Institute, New York, New York 10021

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

gamma -Glutamyl carboxylase is an integral membrane protein required for the posttranslational modification of vitamin K-dependent proteins. The main recognition between the enzyme and its substrates is through an 18-amino acid propeptide. It has been reported that this binding site resides in the amino-terminal third of the gamma -glutamyl carboxylase molecule (Yamada, M., Kuliopulos, A., Nelson, N. P., Roth, D. A., Furie, B., Furie, B. C., and Walsh, C. T. (1995) Biochemistry 34, 481-489). In contrast, we found the binding site in the carboxyl half of the gamma -glutamyl carboxylase. We show that the carboxylase may be cleaved by trypsin into an amino-terminal 30-kDa and a carboxyl-terminal 60-kDa fragment joined by a disulfide bond(s), and the propeptide binds to the 60-kDa fragment. The sequence of the amino terminus of the 60-kDa fragment reveals that the primary trypsin-sensitive sites are at residues 349 and 351. Furthermore, the tryptic fragment that cross-links to the propeptide also reacts with an antibody specific to the carboxyl portion of the gamma -glutamyl carboxylase. In addition, cyanogen bromide cleavage of bovine gamma -glutamyl carboxylase cross-linked to the peptide comprising residues TVFLDHENANKILNRPKRY of human factor IX yields a cross-linked fragment of 16 kDa from the carboxyl half of the molecule, the amino-terminal sequence of which begins at residue 438. Thus, the propeptide binding site lies carboxyl-terminal to residue 438 and is predicted to be in the lumen of the endoplasmic reticulum.


INTRODUCTION

gamma -Glutamyl carboxylation, accomplished by the enzyme gamma -glutamyl carboxylase, is a posttranslational modification essential for the biological activities of a number of vitamin K-dependent proteins. The importance of gamma -glutamyl carboxylation is demonstrated by the various functions of the vitamin K-dependent proteins. The best characterized functions are related to coagulation and are exemplified by proteins such as prothrombin, factor VII, factor IX, factor X, protein C, and protein S. In addition, there are two bone proteins, osteocalcin and matrix Gla protein (1), and the newly discovered growth arrest-specific protein Gas 6 (2).

The gamma -glutamyl carboxylation reaction occurs in the endoplasmic reticulum (3-5), where the enzyme gamma -glutamyl carboxylase uses the small substrates carbon dioxide, oxygen, and vitamin K hydroquinone to convert specific glutamic acid residues of the vitamin K-dependent protein into the gamma -carboxyl glutamic acid Gla. During the process of gamma -glutamyl carboxylation, the vitamin K hydroquinone is converted to vitamin K epoxide, which must be recycled to vitamin K hydroquinone by the enzyme epoxide reductase for the reaction to continue.

The enzymatic activity of the gamma -glutamyl carboxylase was first discovered in the postmitochondrial supernatant of hepatocytes (6). Numerous early studies used microsomes as the crude enzyme sources and the pentapeptide FLEEL as the in vitro substrate to establish a basic understanding of gamma -glutamyl carboxylation (7). By comparing the cDNA-deduced amino acid sequences of different vitamin K-dependent proteins, Pan and Price (8) proposed that the highly conserved propeptide sequences of the vitamin K-dependent proteins function as a recognition site for the enzyme gamma -glutamyl carboxylase. This hypothesis was confirmed by Knobloch and Suttie (9), who demonstrated that the factor X propeptide stimulated the incorporation of 14CO2 into the substrate FLEEL. The recognition site was further elucidated by Jorgensen et al. (10). Subsequently, propeptide-containing peptides were demonstrated to have a Km that was three orders of magnitude lower than the pentapeptide substrate FLEEL for the enzyme gamma -glutamyl carboxylase (11, 12).

Further elucidation of the mechanisms of action of the carboxylase was hindered by the lack of a purified enzyme. To begin a systematic study we made a recombinant peptide, FIXQ/S,1 which contains the propeptide and the complete Gla domain sequence of human factor IX (12), and successfully used it as an affinity ligand to purify gamma -glutamyl carboxylase to near homogeneity in a single step purification (13). We were then able to clone the complete cDNA sequence of gamma -glutamyl carboxylase using the deduced amino acid sequence of a tryptic fragment (14).

The interaction between gamma -glutamyl carboxylase and its substrate is one of the most interesting aspects of gamma -glutamyl carboxylation, and the major factor determining this interaction is the propeptide of the various vitamin K-dependent proteins. Not only does the gamma -glutamyl carboxylase recognize the propeptide sequence, but it also processes multiple modification sites in a single substrate molecule by a processive mechanism (15).

We report here that the major propeptide binding site is in the hydrophilic, soybean seed lipoxygenase-like domain of the carboxylase molecule, which is predicted to reside in the lumen of the endoplasmic reticulum. This is in contradiction to the site proposed by Yamada et al. (16) and Sugiura et al. (17).


EXPERIMENTAL PROCEDURES

Materials

All chemicals were reagent grade. Disuccinimidyl suberate (DSS) and Iodobeads were purchased from Pierce. Na125I was from DuPont NEN. CentriPrep-30 was from Amicon. Immobilon-P was from Millipore. PVDF membranes were purchased from Bio-Rad. The ECL Western blotting detection reagent was from Amersham Corp. SP-Sepharose was from Pharmacia Biotech Inc. Protease inhibitors H-D-Phe-Phe-Arg-chloromethylketone and H-D-Phe-Pro-Arg chloromethylketone were from Bachem. Aprotinin, pepstatin A, and trypsin were purchased from Boehringer Mannheim. Leupeptin, phenylmethylsulfonyl fluoride, and CHAPS were obtained from Sigma. Peptides pro-FIX19 (AVFLDHENANKILNRPKRY), pro-FIX19-16BPA (TVBLDHENANKILNRPKRY; B is p-benzoylphenylalanine (BPA)), hbGC220-234 (CDADWVEGYSMEYLSR), and hbGC709-723 (CGRPSLEQLAQEVTYA) were obtained from Chiron (an amino-terminal cysteine was added to hbGC220-234 and hbGC709-723 for conjugation to keyhole limpet hemocyanin). Recombinant peptide FIXQ/S was prepared as described (12). Endoglycosidase H (Endo H) was purchased from New England Biolabs.

Cleavage of gamma -Glutamyl Carboxylase by Limited Trypsinization

gamma -Glutamyl carboxylase was affinity-purified by elution method II as described (13). pro-FIX19 and protease inhibitors (when used) were removed before trypsin cleavage by ultrafiltration using a CentriPrep-30 unit with deCIP buffer (25 mM MOPS, pH 7.5, 500 mM NaCl, and 0.3% CHAPS). A pilot reaction was run for each batch of gamma -glutamyl carboxylase and trypsin to determine the optimal condition for limited trypsin cleavage. Because limited trypsin cleavage could only be obtained with intact, enzymatically active gamma -glutamyl carboxylase, the cleavage was carried out at 4 °C. Trypsin cleavage was stopped by adding H-D-Phe-Pro-Arg chloromethylketone to a final concentration of 1.6 µM.

DSS-mediated Chemical Cross-linking

Peptides pro-FIX19 and FIXQ/S were radiolabeled with Na125I using Iodobeads according to the manufacturer. To increase cross-linking efficiency, the enzymatically active, intact or the limited trypsinized gamma -glutamyl carboxylase (in elution buffer) was preincubated with propeptide-containing peptides (e.g. 0.5-2 µM 125I-peptide or 0.5-2 µM 125I-peptide with 40-60-fold excess unlabeled competitor) at 4 °C for 1 h before DSS was added to a final concentration of 50-200 µM. Cross-linking was carried out at 4 °C and at times varying from 20 min to 3 h before it was stopped with 50 mM Tris-HCl, pH 8.8.

Cross-linking pro-FIX19-16BPA to the gamma -Glutamyl Carboxylase

pro-FIX19-16BPA (16) was cross-linked to the carboxylase by exposure to a 365-nm UV lamp (Cole-Parmer E-97600) for 15 min at a distance of 15 cm. During photo cross-linking the sample was maintained on ice.

Generation of Antibodies against Synthetic Peptides Derived from gamma -Glutamyl Carboxylase Sequence

Synthetic peptides hbGC220-234 and hbGC709-723 were conjugated to keyhole limpet hemocyanin through an amino-terminal cysteine. One µg of conjugated peptide in Freund's complete adjuvant was subcutaneously inoculated into New Zealand White rabbits. One microgram of each conjugated peptide in Freund's incomplete adjuvant was used to boost the immunity 2 weeks after the first inoculation.

Identification of Tryptic Fragments by Immunoblotting

Forty ng of the limited trypsinized carboxylase was analyzed by reducing SDS-PAGE (18) and electroblotted onto Immobilon-P (Millipore). The membrane was probed with 200-fold diluted anti-hbGC-amino acids antiserum and followed by a horseradish peroxidase-coupled anti-rabbit antibody. ECL Western blotting detection reagent was used as recommended by the manufacturer to reveal the reactive fragment.

Determination of the Propeptide Binding Region by Amino Acid Sequencing

gamma -Glutamyl carboxylase was purified as described (13), except that 125I-pro-FIX19 or FIXQ/S was used in the elution. Ten to 100 µg of affinity-purified gamma -glutamyl carboxylase was concentrated 6-8-fold on CentriPrep-30 units. Cross-linking reactions were carried out at 4 °C in 10-15 ml of 25 mM MOPS, pH 7.5, 500 mM NaCl, 15% glycerol, 0.4% phosphatidylcholine, and 0.25% CHAPS with 50-200 µM DSS. Sixty-five percent ammonium sulfate was used to precipitate the proteins from the pro-FIX19 cross-linking mixture. Proteins were dissolved in 5 ml of 25 mM MOPS, pH 6.5, 0.5% CHAPS, and 10% glycerol and sonicated before being batch-adsorbed onto SP-Sepharose. The gamma -glutamyl carboxylase and the cross-linked gamma -glutamyl carboxylase were co-eluted from an SP-Sepharose column with a 0-1 M NaCl gradient in 25 mM MOPS, pH 7.5, 10% glycerol, 0.02% phosphatidylcholine, and 0.02% CHAPS. The gamma -glutamyl carboxylase-containing fractions were further concentrated on CentriPrep-30, subjected to SDS-PAGE, electroblotted onto a nitrocellulose membrane, cleaved with cyanogen bromide, concentrated, refractionated by SDS-PAGE, and then analyzed by amino acid sequencing.

Sequencing of the 30- and 60-kDa Fragments

The determination of the amino termini of the limited tryptic fragments was done at the Harvard Microchemistry Facility.

Quantitation of Radioactive Bands in PAGE

The radioactive bands were imaged with a Molecular Dynamics Storm 840 PhosphorImager, and quantitation was achieved with ImageQuant software.


RESULTS AND DISCUSSION

The gamma -glutamyl carboxylase is a 758-amino acid protein that migrates on reducing SDS-PAGE as a 94-kDa protein. The enzymatically active gamma -glutamyl carboxylase is cleaved by limited trypsin digestion into two major fragments with electrophoretic mobilities of approximately 60 and 30 kDa (Fig. 1, lane 3). The 60-kDa fragment reacts with an antibody made to a 15-amino acid peptide corresponding to residues 709-723, whereas the 30-kDa fragment reacts with an antibody made to residues 220-234 near the amino terminus of the gamma -glutamyl carboxylase (Fig. 2). In the absence of the propeptide or during prolonged trypsin cleavage, the 60-kDa fragment is converted into a 50-kDa fragment. Because the 50-kDa fragment, which is identified with the cross-linked fragment, failed to react with an antibody made to residues near the carboxyl terminus of the 60-kDa fragment (Fig. 2), we postulated that the 50-kDa fragment arises by cleavage near the carboxyl terminus of the 60-kDa fragment. From the results of the immunoblot, we predicted that both the 60- and 50-kDa fragments were derived from the carboxyl half and the 30-kDa fragment from the amino-terminal half of the gamma -glutamyl carboxylase. We also predicted that, although the 50- and 60-kDa fragments have different carboxyl-terminal sequences, they would have the same amino-terminal sequence.


Fig. 1. Limited trypsin digestion of the affinity-purified gamma -glutamyl carboxylase. A reducing SDS-PAGE silver-stained gel is depicted. Lane 1, size markers; lane 2, gamma -glutamyl carboxylase; lane 3, trypsinized gamma -glutamyl carboxylase; lane 4, same as lane 3, except incubated in Endo H buffer; lane 5, same as lane 4, except treated with Endo H.
[View Larger Version of this Image (60K GIF file)]


Fig. 2. Identification of the tryptic fragments of gamma -glutamyl carboxylase by region-specific antibodies. A, reducing SDS-PAGE of gamma -glutamyl carboxylase visualized by an antibody to residues 709-724 of the gamma -glutamyl carboxylase. Lane 1, gamma -glutamyl carboxylase; lane 2, its limited trypsin digestion product. B, as in A, except visualization is with an antibody made to residues 220-234 of the gamma -glutamyl carboxylase. C, reducing SDS-PAGE of gamma -glutamyl carboxylase visualized by silver staining. Lane 1, uncleaved gamma -glutamyl carboxylase; lane 2, its limited trypsin digestion product.
[View Larger Version of this Image (51K GIF file)]

To identify the primary trypsin-sensitive sites in the carboxylase, affinity-purified bovine gamma -glutamyl carboxylase was cleaved by limited trypsin digestion, fractionated by reducing SDS-PAGE, and transferred to PVDF membranes for amino acid sequence analysis. Sequence analysis revealed that the 50- and 60-kDa fragments arise from cleavage following arginines 349 and 351 (Fig. 3). We also attempted to determine the sequence of the 30-kDa fragment. Analysis of amino acid composition predicted 15 pmol of the 30-kDa fragment compared with 7 pmol each of the 60- and 50-kDa fragments in the sample that was used for sequence analysis. This result indicated that the blotting efficiency for each fragment was similar and predicts that, at each step in amino acid sequence analysis, the sum of the amino acid yield of the 50- and 60-kDa fragments should equal the yield at each step for the 30-kDa fragment. Because we had previously determined that the amino terminus was blocked (14), however, we expected sequence from the amino terminus only if trypsin cleavage had occurred.


Fig. 3. Sequence of the bovine gamma -glutamyl carboxylase. *, residues that differ from the human gamma -glutamyl carboxylase. Boldface residues, those mutated in the study of Sugiura et al. (17). Arrows, the most sensitive trypsin cleavage sites of the bovine gamma -glutamyl carboxylase. Boxed region, sequence of a fragment obtained from cyanogen bromide cleavage of bovine gamma -glutamyl carboxylase cross-linked to 125I-pro-FIX19. Shaded residues, potential downstream cyanogen bromide cleavage sites.
[View Larger Version of this Image (56K GIF file)]

We obtained sequence from the amino terminus of the 30-kDa fragment, indicating a trypsin cleavage site at lysine 19 of the bovine carboxylase. Because the yield from each sequencing cycle of the 30-kDa fragment is lower than the sum of the yields of the 50- and 60-kDa fragments, this is consistent with a preparation in which the 30-kDa band consists of about 50% of a gamma -glutamyl carboxylase fragment with a blocked amino terminus and about 50% with its amino terminus cleaved at lysine 19 (Fig. 3).

Thus, if no other accessible tryptic cleavage sites occur before residue 349, the band that migrates on SDS-PAGE at 30 kDa would have actual molecular masses (excluding any modifications) of 40.2 (uncleaved form) and 38.2 (cleaved form) kDa. The larger carboxyl-terminal fragment, which migrates at 60 kDa on SDS-PAGE, would have an actual mass of 47.4 kDa, again excluding modifications. The difference in the mobility and expected mass of the 30-kDa fragment could be due to anomalous migration on SDS-PAGE or to an additional trypsin cleavage before residue 349. However, the difference in the relative molecular mass of the 60-kDa fragments determined by mobility on reducing SDS-PAGE and that predicted by the amino acid sequence appears to be due to glycosylation of the potential glycosylation sites in the luminal, carboxyl portion of the gamma -glutamyl carboxylase. Fig. 1, lane 5, shows that removal of sugars from the carboxylase with Endo H results in a change in the migration of the 60-kDa fragment to that expected of an approximately 50-kDa fragment. In contrast, there is no apparent change in the relative mobility of the 30-kDa fragment following treatment with Endo H. A further insight gained from limited trypsin cleavage is that the 30- and 60-kDa fragments are linked by one or more disulfide bonds, as they are not resolved on SDS-PAGE except when the reducing agent is present (Fig. 4).


Fig. 4. Demonstration that the 30- and 60-kDa fragments of the gamma -glutamyl carboxylase are joined by a disulfide bond(s). Lane 1, size markers; lane 2, trypsin-treated carboxylase subjected to SDS-PAGE; lane 4, same sample subjected to reducing PAGE. The samples are separated by a blank lane to prevent the reducing agent from diffusing between wells.
[View Larger Version of this Image (55K GIF file)]

Before attempting to determine the site on the gamma -glutamyl carboxylase where the propeptide of factor IX binds, we cross-linked FIXQ/S or pro-FIX19 to the gamma -glutamyl carboxylase with different chemical cross-linkers to find one that gave the most efficient cross-linking. We tried 1-ethyl-3-3(3-dimethylaminopropyl)-carbodiimide hydrochloride, dithiobis-(succinimidyl propionate), and DSS. The free amine-specific, nonreversible cross-linker disuccinimidyl suberate gave the highest cross-linking efficiency. Fig. 5 demonstrates that cross-linking of FIXQ/S to gamma -glutamyl carboxylase results in a shift of approximately 40% of the gamma -glutamyl carboxylase to a mobility consistent with a mass of about 100 kDa.


Fig. 5. Efficiency of DSS cross-linking. Silver-stained PAGE of gamma -glutamyl carboxylase cross-linked to FIXQ/S.
[View Larger Version of this Image (26K GIF file)]

To determine which tryptic fragment contains the propeptide binding site, we digested the gamma -glutamyl carboxylase with trypsin using conditions known to generate the 30- and 60-kDa fragments. The still enzymatically active gamma -glutamyl carboxylase was then cross-linked to 125I-pro-FIX19 or FIXQ/S. Fig. 6 shows that cross-linking is observed when either pro-FIX19 or FIXQ/S is used for cross-linking and that cold pro-FIX19 effectively competes with either radioactive peptide. Fig. 6 also clearly demonstrates that the propeptide of factor IX binds to the carboxyl-terminal 60-kDa fragments as well as the 50-kDa fragment of the gamma -glutamyl carboxylase molecule. This observation has been repeated many times with different preparations of gamma -glutamyl carboxylase and with several different propeptides, including pro-FIX19, FIXQ/S, and biotin-pro-FIX19-biotin. Identical results were obtained whether the cross-linking was done before or after the limited trypsin digestion. The only requirement appears to be that the gamma -glutamyl carboxylase is enzymatically active. The fact that only active carboxylase will cross-link to the propeptide is further evidence for the specificity of the cross-linking reaction.


Fig. 6. Chemical cross-linking of the propeptide to the native and limited trypsinized gamma -glutamyl carboxylase. The cross-linking conditions are indicated above the reducing SDS-PAGE silver-stained gel (upper) and its autoradiogram (lower). pro-FIX19 is the propeptide sequence of human factor IX, and FIXQ/S is the propeptide plus the Gla domain sequences of human factor IX. Thick and thin arrows on left, FIXQ/S and pro-FIX19 cross-linked fragment, respectively.
[View Larger Version of this Image (79K GIF file)]

During the course of this work Yamada et al. (16) published that the propeptide binding site was found within the amino-terminal 259 amino acids of the recombinant gamma -glutamyl carboxylase. Because our results were different, we attempted to resolve the cause of the difference. A photochemical peptide, pro-FIX19-16BPA, with sequence identical to that used by Yamada et al. (16) was obtained and used for photochemical cross-linking. Fig. 7 demonstrates that pro-FIX19-16BPA predominantly cross-linked to the 60-kDa fragment no matter whether the cross-linking was accomplished photochemically or was DSS-mediated. Fig. 7A depicts a silver-stained gel of the autoradiograph shown in Fig. 7B and demonstrates that both the 60- and 30-kDa fragments are present in our preparation. To confirm further that binding was predominately in the 60-kDa fragment, we trypsin-cleaved another carboxylase sample and photochemically cross-linked it to iodinated pro-FIX19-16BPA. We then subjected the product to reducing and nonreducing SDS-PAGE and quantitated the amount of radioactivity in each band with a PhosphorImager. Fig. 8 shows a radioactive image of photochemically cross-linked gamma -glutamyl carboxylase fractionated by nonreducing and reducing PAGE. The 60-kDa band of the reduced sample contained 87% of the radioactivity found in the 94-kDa unreduced gamma -glutamyl carboxylase. Approximately 5% appeared in the 30-kDa band, and the remainder was in the uncleaved 94-kDa band. Thus, there was no selective loss of a cleaved fragment in our preparation.


Fig. 7. SDS-PAGE gels of pro-FIX19-16BPA cross-linked to the carboxylase. Lane 1, molecular weight standards; lanes 2 and 3 are photochemically cross-linked; lanes 4 and 5 are cross-linked with DSS. Lanes 3 and 5, same as lanes 2 and 4 except for the presence of an excess of unlabeled pro-FIX19-16BPA. A, silver-stained gel; B, autoradiograph of the same gel.
[View Larger Version of this Image (39K GIF file)]


Fig. 8. Quantitation of the amount of radioactivity in the 94-, 60-, and 30-kDa bands. A sample of trypsin-cleaved 94-kDa carboxylase photochemically cross-linked to pro-FIX19-16BPA was subjected to SDS-PAGE under nonreducing (lane 1) and reducing (lane 2) conditions, and the radioactive bands were imaged with a Molecular Dynamics Storm 840 PhosphorImager; quantitation was achieved with ImageQuant software. Rectangles, regions that were analyzed. Rectangle 5 was used for background.
[View Larger Version of this Image (82K GIF file)]

We have made numerous attempts to narrow further the region to which the propeptide binds. These experiments were hampered by the difficulties in obtaining complete cleavage of the carboxylase by either enzymatic or chemical methods. Nevertheless, we were able to obtain an amino-terminal sequence from a small cyanogen bromide fragment of gamma -glutamyl carboxylase cross-linked to pro-FIX19. The gamma -glutamyl carboxylase was chemically cross-linked to 125I-labeled pro-FIX19 by disuccinimidyl suberate. The cross-linked gamma -glutamyl carboxylase was then fractionated by reducing SDS-PAGE and transferred to a PVDF membrane. The location of the cross-linked carboxylase was determined by autoradiography, and it was excised from the membrane and cleaved in situ with cyanogen bromide. The resulting cyanogen bromide fragments were again fractionated by reducing SDS-PAGE and transferred to a PVDF membrane for sequence analysis. The primary sequence obtained from the amino terminus of this radioactive cyanogen bromide fragment was KDHADMLKQYATC, which corresponds to residues 438-450 of the gamma -glutamyl carboxylase and is shown boxed in Fig. 3. In this case, cyanogen bromide cleavage occurred at a tryptophan rather than the expected methionine residue. Although not common, other examples of cleavage at tryptophan residues by cyanogen bromide have been reported (19). Secondary and tertiary sequences were also present in the sequence analysis. The secondary sequence resulted from cleavage after the methionine at 443, whereas the tertiary sequence was apparently the result of unexplained cleavage following histidine 440.

The radioactive band migrated as 16 kDa (Fig. 9); however, because it is cross-linked to pro-FIX19, which is 2.3 kDa, and there is a potential N-glycosylation site, we estimate that the size is considerably less than 16 kDa. The most reasonable assumption is that it terminates at residue 507, the next methionine in the carboxylase. Cleavage at the next methionine beyond methionine 507 (methionine 579) would be expected to give a 17.7-kDa fragment, which, if cross-linked, would certainly migrate as a larger fragment. This size would probably be even larger, because four of the nine potential N-glycosylation sites of the gamma -glutamyl carboxylase are located between residues 438 and 579. The cyanogen bromide fragment that we isolated and sequenced appears to be the major species of labeled fragment, because there are no other radioactive bands visible on the gel. The 125I-proFIX19 used for cross-linking was also used for a size marker, making it very unlikely that any cross-linked peptides could have run off the end of the gel during PAGE analysis. Furthermore, three overlapping sequences obtained from the radioactive cyanogen bromide band are all found within the larger tryptic fragment that we identified by immunoblotting and amino acid sequencing.


Fig. 9. Autoradiograph of the carboxylase cyanogen bromide fragment cross-linked to gamma -glutamyl carboxylase. The fragments recovered from cyanogen bromide cleavage were subjected to 10-20% gradient, reducing SDS-PAGE analysis. After transfer to a PVDF membrane, the region containing the radioactive peptide was excised and sequenced.
[View Larger Version of this Image (41K GIF file)]

Sugiura et al. (17) recently published a mutagenesis study on bovine carboxylase expressed in Chinese hamster ovary cells (17). They concluded from their studies that "lysine 217 or lysine 218 may be key for substrate and/or propeptide recognition or for catalysis." Chinese hamster ovary cells contain endogenous carboxylase activity, and it is therefore difficult to interpret their kinetic data. Interpretation is especially difficult in the relevant mutants in which low activity levels of bovine carboxylase were encountered. It is of note, however, that they observed that higher propeptide concentrations were required to stimulate the incorporation of 14CO2 into FLEEL in the gamma -glutamyl carboxylase mutated at positions 513 and 515, which would support the data presented in this article.

The differences in the results reported here and those reported by Yamada et al. (16) and confirmed by Sugiura et al. (17) are probably due to their implicit assumption that the migration of proteins on gels is directly proportional to their molecular mass. However, it is true that some regions of the two fragments are in very close proximity, as shown by the fact that the 60- and 30-kDa fragments are joined by a disulfide bond(s). Therefore, it is possible that lysines 217 and 218 are in close proximity to residues in the carboxyl half of the carboxylase molecule and that their conditions were sufficiently different from ours that, in their hands, the propeptide reacted with amino-terminal residues rather than the carboxyl-terminal residues that we saw. Although there is serious difficulty in interpreting some of the data of Sugiura et al. (17) because of the endogenous carboxylase activity, their data suggest that mutations at residues 234-235, 359-361, 406-408, and 513-515 all affect propeptide binding. It is difficult to draw firm conclusions until there is a more extensive characterization of their mutated enzymes in a system in which there is no endogenous gamma -glutamyl carboxylase. But it appears that the data of Sugiura et al. (17) agree as well with our data as they do with the data of Yamada et al. (16).

Our data, derived from both cyanogen bromide and tryptic cleavage, demonstrate clearly that the propeptide is cross-linked to the carboxyl, luminal portion of the gamma -glutamyl carboxylase. We conclude that the propeptide is cross-linked to residues between lysine 438 and methionine 507. Thus, this area is a prime candidate for further mutational analysis.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant HL48318 (to D. W. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Biology Dept., University of North Carolina, Chapel Hill, NC 27599-3280. Tel.: 919-962-0597; Fax: 919-962-0597; E-mail: dws{at}email.unc.edu.
1   The abbreviations used are: FIXQ/S, recombinant peptide comprising residues -18 to +41 of profactor IX with mutations T18A, R4Q, R1S, and M19I; pro-FIX19, peptide comprising residues TVFLDHENANKILNRPKRY of human factor IX; pro-FIX19-16BPA, peptide comprising residues TVBLDHENANKILNRPKRY; BPA, p-benzoylphenylalanine; DSS, disuccinimidyl suberate; PVDF, polyvinylidene difluoride; CHAPS, 3-(3-cholamidopropyl)-dimethylammonio)-1-propanesulfonate; Endo H, endoglycosidase H; MOPS, 4-morpholinepropanesulfonic acid; PAGE, polyacrylamide gel electrophoresis.

REFERENCES

  1. Price, P. A. (1989) Connect. Tissue Res. 21, 51-57 [Medline] [Order article via Infotrieve]
  2. Manfioletti, G., Brancolini, C., Avanzi, G., and Schneider, C. (1993) Mol. Cell. Biol. 13, 4976-4985 [Abstract]
  3. Carlisle, T. L., and Suttie, J. W. (1980) Biochemistry 19, 1161-1167 [Medline] [Order article via Infotrieve]
  4. Wallin, R., Stanton, C., and Hutson, S. M. (1993) Biochem. J. 291, 723-727 [Medline] [Order article via Infotrieve]
  5. Bristol, J. A., Ratcliffe, J. V., Roth, D. A., Jacobs, M. A., Furie, B. C., and Furie, B. (1996) Blood 88, 2585-2593 [Abstract/Free Full Text]
  6. Esmon, C. T., Sadowski, J. A., and Suttie, J. W. (1975) J. Biol. Chem. 250, 4744-4748 [Abstract]
  7. Suttie, J. W. (1985) Annu. Rev. Biochem. 54, 459-477 [CrossRef][Medline] [Order article via Infotrieve]
  8. Pan, L. C., and Price, P. A. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 6109-6113 [Abstract]
  9. Knobloch, J. E., and Suttie, J. W. (1987) J. Biol. Chem. 262, 15334-15337 [Abstract/Free Full Text]
  10. Jorgensen, M. J., Cantor, A. B., Furie, B. C., Brown, C. L., Shoemaker, C. B., and Furie, B. (1987) Cell 48, 185-191 [Medline] [Order article via Infotrieve]
  11. Ulrich, M. M. W., Furie, B., Jacobs, M. R., Vermeer, C., and Furie, B. C. (1988) J. Biol. Chem. 263, 9697-9702 [Abstract/Free Full Text]
  12. Wu, S.-M., Soute, B. A. M., Vermeer, C., and Stafford, D. W. (1990) J. Biol. Chem. 265, 13124-13129 [Abstract/Free Full Text]
  13. Wu, S. M., Morris, D. P., and Stafford, D. W. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 2236-2240 [Abstract]
  14. Wu, S.-M., Cheung, W.-F., Frazier, D., and Stafford, D. (1991) Science 254, 1634-1636 [Medline] [Order article via Infotrieve]
  15. Morris, D. P., Stevens, R. D., Wright, D. J., and Stafford, D. W. (1995) J. Biol. Chem. 270, 30491-30498 [Abstract/Free Full Text]
  16. Yamada, M., Kuliopulos, A., Nelson, N. P., Roth, D. A., Furie, B., Furie, B. C., and Walsh, C. T. (1995) Biochemistry 34, 481-489 [Medline] [Order article via Infotrieve]
  17. Sugiura, I., Furie, B., Walsh, C. T., and Furie, B. C. (1996) J. Biol. Chem. 271, 17837-17844 [Abstract/Free Full Text]
  18. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  19. Boulware, D. W., Goldsworthy, P. D., Nardella, F. A., and Mannik, M. (1985) Mol. Immunol. 22, 1317-1322 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.